



COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT
PROVIDER HEALTH ADVISORY

Reminder: When to Administer the RSV Immunizations

To protect infants from RSV

Date: January 30, 2024

Contact: Rick Rosen, MD, MPH, frosen@co.slo.ca.us, 805-781-5500

Please see the attached CDC communication about seasonal administration of maternal RSV vaccine.

As a reminder, the **maternal RSV vaccine season is September 1 through January 31** for pregnant people during 32–36 weeks gestation to protect infants from lower respiratory tract disease after birth. (Product: Pfizer’s Abrysvo)

The **season to immunize infants of unvaccinated mothers with nirsevimab is October 1 through March 31**. (Product: nirsevimab, or Beyfortus)

Finally, a reminder that the Public Health Department still has a small supply of nirsevimab available to infants who are uninsured or are eligible for Medi-Cal. Clinic locations are Grover Beach, Paso Robles, and San Luis Obispo. Providers may fax referrals to 805-781-5543 and Public Health staff will follow up with patients to schedule, or patients/families may call 805-781-5500 directly to schedule.

Thank you for your attention to this important effort.

Public Health Department

2191 Johnson Avenue | San Luis Obispo, CA 93401 | (P) 805-781-5500 | (F) 805-781-5543

www.slopublichealth.org



January 26, 2024

Reminder of Recommendations for Seasonal Administration of Maternal RSV Vaccine

The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend the [RSV vaccination \(Pfizer Abrysvo\) for pregnant people](#) during 32–36 weeks gestation using seasonal administration to protect infants against RSV-associated lower respiratory tract disease (LRTD) after birth. In most of the continental United States, the RSV vaccine should be given to pregnant people from September 1 through January 31, regardless of year-to-year circulation, when infants would be born during increased RSV activity, and the vaccination would provide the most benefits to the infant against RSV-associated LRTD after birth. Jurisdictions that have different RSV seasonality from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, may consider RSV vaccination of pregnant people after January 31. Infants born to unvaccinated mothers should receive nirsevimab, a long-acting monoclonal antibody that provides immediate protection to the infant against RSV-associated LRTD.

Recommendations for Healthcare Providers on the Seasonal Administration of the RSV Vaccine (Pfizer Abrysvo)

- In most of the continental United States, administer the maternal RSV vaccine (Pfizer Abrysvo) from September 1 through January 31.
 - Healthcare providers who administer the RSV vaccine to pregnant people after January 31 should encourage patients to check with their insurance plans on coverage details, as coverage and cost-sharing by private insurance plans may vary after January 31. Providers should consider submitting an insurance test claim to estimate out-of-pocket costs.
- In jurisdictions where seasonality differs from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of administering the RSV vaccine (Pfizer Abrysvo) for pregnant people.
- CDC recommends protecting all infants against RSV-associated LRTD through either the RSV vaccine for pregnant people (Pfizer Abrysvo) or infant receipt of nirsevimab. Administration of both products is not needed for most infants.
 - For infants age less than 8 months born to unvaccinated mothers, healthcare providers should administer nirsevimab from October 1 through

March 31; however, healthcare providers can administer nirsevimab outside of this timeframe based on local epidemiology

For More Information:

- [Frequently Asked Questions about RSVpreF \(Abrysvo\) Vaccine for Pregnant People](#)
- [Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023](#)
- [Frequently Asked Questions about RSV Immunization with Monoclonal Antibody for Children 19 months and Younger](#)

The Office of Emergency Risk Communication in the Office of Communications is responsible for the management of all COCA Products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov
[Clinician Outreach and Communication Activity](#)—resources for healthcare providers
[COCA RSS Feed](#)—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
[Crisis & Emergency Risk Communication Training](#)—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
[Health Alert Network](#)—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories



CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.